Maxidex (dexamethasone eye drops, suspension) / Novartis, Harrow Health - LARVOL DELTA

EMAT: Elimination of Minimal Residual Disease After Transplant (clinicaltrials.gov) - P2 | N=30 | Active, not recruiting | Sponsor: Medical College of Wisconsin | Recruiting ➔ Active, not recruiting

Enrollment closed • Minimal residual disease • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation

Bilateral acanthamoeba keratitis following photorefractive keratectomy: a rare, severe complication. (PubMed, Int J Surg Case Rep) - "PRK with mitomycin C was performed in both eyes. After the procedure, the patient was treated with moxifloxacin-dexamethasone eye drops, lubricating eye drops, and therapeutic contact lenses...Cold water from the tap had been splashed directly into the patient's eyes in the first days following the procedure, which may have caused the infection. Preoperative counseling regarding contact with water is crucial in preventing this serious complication."

Journal • Infectious Disease • Keratitis • Ocular Inflammation • Ophthalmology • Pain

ESMART: European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors (clinicaltrials.gov) - P1/2 | N=285 | Recruiting | Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

New P1/2 trial • Hematological Malignancies • Oncology • Pediatrics

ESMART: European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors (clinicaltrials.gov) - P1/2 | N=455 | Recruiting | Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Trial completion date: Aug 2027 ➔ Feb 2031 | Trial primary completion date: Aug 2027 ➔ Feb 2031

Trial completion date • Trial primary completion date • Hematological Malignancies • Oncology • Pediatrics

ESMART: European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors (clinicaltrials.gov) - P1/2 | N=397 | Recruiting | Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | N=285 ➔ 397 | Trial completion date: Dec 2020 ➔ Jan 2022 | Trial primary completion date: Dec 2020 ➔ Jan 2022

Enrollment change • Trial completion date • Trial primary completion date • Pediatrics

ESMART: European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors (clinicaltrials.gov) - P1/2 | N=460 | Recruiting | Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Trial completion date: Jan 2022 ➔ Aug 2027 | Trial primary completion date: Jan 2022 ➔ Aug 2027

Trial completion date • Trial primary completion date • Hematological Malignancies • Oncology • Pediatrics

Venetoclax Plus Inotuzumab for B-ALL (clinicaltrials.gov) - P1 | N=23 | Active, not recruiting | Sponsor: Dana-Farber Cancer Institute | Recruiting ➔ Active, not recruiting | Trial completion date: Jun 2026 ➔ Dec 2026

Enrollment closed • Trial completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • B Cell Lymphoma • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD22

Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - P2 | N=46 | Completed | Sponsor: Dana-Farber Cancer Institute | Active, not recruiting ➔ Completed

Trial completion • Hematological Malignancies • Multiple Myeloma • Oncology

Acute posterior multifocal placoid pigment epitheliopathy complicated by a stroke, leading to the diagnoses of lupus anticoagulant and hypercysteinemia. (PubMed, J Fr Ophtalmol) - "APMPPE is a well-established disease, and neurological complications are rare. Cerebral vasculitis and strokes are the most commonly reported neurological lesions. The search for antiphospholipid syndrome and hypercysteinemia in the first-line work-up of APMPPE should be considered."

Journal • Cardiovascular • Genetic Disorders • Hematological Disorders • Immunology • Inflammatory Arthritis • Ocular Inflammation • Ophthalmology • Uveitis • Vasculitis

Engineering Mixed Micelle-Loaded Contact Lenses for Sustained Ocular Delivery of Dexamethasone: In Vitro and In Vivo Studies. (PubMed, ACS Appl Bio Mater) - "Conventional dexamethasone eye drops suffer from poor ocular bioavailability due to rapid tear turnover and limited corneal residence, necessitating frequent dosing and posing challenges in chronic ocular therapies...In conclusion, this dual-surfactant micelle platform markedly enhances the therapeutic potential of drug-eluting contact lenses, offering a safe, sustained, and patient-compliant alternative for managing ocular inflammation. These findings support further clinical translation of micelle-integrated lenses as next-generation ocular drug delivery systems."

Journal • Preclinical • Inflammation • Ocular Inflammation • IL6

COHOST: Carbon Monoxide Hyperbaric Oxygen With Steroid Therapy (clinicaltrials.gov) - P1/2 | N=20 | Not yet recruiting | Sponsor: University of Nebraska | Trial primary completion date: Jan 2027 ➔ Jul 2027

Trial primary completion date • CNS Disorders • Movement Disorders • Parkinson's Disease

Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma (clinicaltrials.gov) - P2 | N=236 | Active, not recruiting | Sponsor: Washington University School of Medicine | Trial completion date: Aug 2025 ➔ Aug 2026

Trial completion date • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation

Treating retinopathy of prematurity with dexamethasone eye drops: a difference-in-differences study in Sweden using register data. (PubMed, Ophthalmology) - "In this population of infants with severe ROP, the introduction of dexamethasone eye drops was associated with a significant reduction in the proportion of infants requiring traditional ROP treatments. A timely administration of low-dose dexamethasone eye drops may serve as a simple, cost-effective, and noninvasive intervention to reduce one of the leading causes of severe visual impairment worldwide. Further studies are needed to confirm our findings."

Journal • Retinal Disorders • Retinopathy of Prematurity

Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - P2 | N=46 | Active, not recruiting | Sponsor: Dana-Farber Cancer Institute | Trial completion date: Jun 2025 ➔ Oct 2025

Trial completion date • Hematological Malignancies • Multiple Myeloma • Oncology

The efficacy of combined povidone-iodine 1% and dexamethasone 0.08% prepared eye drops in treating post-viral corneal subepithelial infiltrates. (PubMed, Indian J Ophthalmol) - "Combined povidone-iodine 1% and dexamethasone 0.08% eye drops offer superior improvement in SEIs, BCVA, and symptom relief, with lower recurrence compared to individual treatments. These findings suggest a potential synergistic effect of combined treatment in managing SEIs."

Clinical • Journal • Allergy • Conjunctivitis • Dry Eye Disease • Endocrine Disorders • Immunology • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology

Acute Central Toxic Keratopathy Induced by Exposure to Chinese Herbal Medicine Fluid for Verruca Plana: A Case Report. (PubMed, Case Rep Ophthalmol Med) - "Thus, tobramycin dexamethasone eye drops and artificial tears were prescribed for her, which proved effective. Her clinical symptoms and signs were both resolved after steroid treatment and remained stable at the 1-month follow-up. Acute central toxic keratopathy could occur after exposure to Chinese herbal medicine fluid, and enhanced topical steroid treatment worked well for alleviating inflammation and reducing corneal opacity."

Journal • Inflammation • Ophthalmology • Pain

Tacrolimus eye drops treatment for recurrent exposure of the Ahmed glaucoma valve tube. (PubMed, Eur J Med Res) - "Treatment with 0.1% tacrolimus eye drops demonstrated satisfactory results in managing recurrent exposure following allogeneic scleral patch graft coverage and autologous scleral tunnel repair, suggesting its potential as an effective alternative to conventional treatments."

Journal • Glaucoma • Ophthalmology • Transplantation

Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement (clinicaltrials.gov) - P2 | N=70 | Completed | Sponsor: Emory University | Active, not recruiting ➔ Completed

Trial completion • Hematological Malignancies • Multiple Myeloma • Oncology

Comparison of Tobramycin-Dexamethasone Combination Eyedrop Versus Artificial Tear Eyedrop for the Management of Presumed Viral Epidemic Conjunctivitis: A Randomized Treatment Trial. (PubMed, Curr Eye Res) - "To compare the efficacy and safety of one-time povidone-iodine (PovI) administration followed by a course of tobramycin-dexamethasone eye drops versus artificial tears in acute viral conjunctivitis (AVC). A course of tobramycin-dexamethasone combination eyedrops after PovI may lead to early symptomatic relief, but recovery was similar to artificial tears by day 7. No significant/sight-threatening complications were observed in any groups."

Journal • Conjunctivitis • Ocular Infections • Ocular Inflammation • Ophthalmology • Pain

Subperiosteal abscess of the orbit: case presentation (SOE 2025) - "The patient was prescribed Amoxicillin 1000mg twice daily, Ibuprofen 400mg twice daily, Dexamethasone eye drops every two hours, Tobramycin eye drops every two hours.The consilium was held... Orbital complications of acute rhinosinusitis are rare but potentially severe. Rapid diagnostic imaging and urgent endoscopic decompression of the abscess prevent permanent loss of vision and further defects of neurological character. endoscopic access should be the first choice in surgical treatment."

Clinical • Ophthalmology

M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers (clinicaltrials.gov) - P1/2 | N=37 | Completed | Sponsor: National Cancer Institute (NCI) | Active, not recruiting ➔ Completed | Trial completion date: Jan 2027 ➔ Mar 2025

Trial completion • Trial completion date • Tumor mutational burden • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Steroid-Induced Diabetes: When Ocular Treatment Becomes a Metabolic Threat (ESPE-ESE 2025) - "We report a case of diabetes induced by dexamethasone eye drops in a 64-year-old patient admitted for the management of nodular prurigo...Healthcare providers should remain vigilant for this potential complication, especially in patients with long-term use. Regular monitoring of blood glucose and timely intervention can prevent long- term complications."

Diabetes • Fatigue • Genetic Disorders • Immunology • Metabolic Disorders • Obesity • Ocular Inflammation • Ophthalmology • Prurigo Nodularis • Type 2 Diabetes Mellitus • Uveitis

Evaluation of timed dexamethasone eye drops to prevent proliferative retinopathy of prematurity: a study protocol for a randomized intervention, multi-centre, double-blinded trial (DROPROP). (PubMed, BMC Pediatr) - P1 | "Timely administration of dexamethasone eye drops may prevent severe ROP from progressing to Type 1 ROP, which requires treatment. This study aims to assess the efficacy and safety of dexamethasone intervention to support its clinical use and national guidelines."

Journal • Ophthalmology • Retinal Disorders • Retinopathy of Prematurity • Strabismus

Iatrogenic Cushing Syndrome and Secondary Adrenal Insufficiency in a Child due to Topical Ocular Corticosteroids: A Case Report. (PubMed, Case Rep Ophthalmol) - "An 11-year-old girl was referred to our ocular inflammation department due to idiopathic, chronic, non-hypertensive, non-granulomatous bilateral anterior uveitis, treated with topical dexamethasone (eye drops, 1 mg/mL) for 1 year...She was treated with methotrexate (15 mg/week, orally), and the topical corticosteroid regimen was progressively tapered and discontinued after 3 months...Although rare, ophthalmologists must be aware of ICS and SAI and prioritize using the least potent corticosteroid for the shortest duration necessary. Additionally, clinicians should avoid abrupt cessation of long-term corticosteroid therapy as this can precipitate an adrenal crisis in the presence of adrenal insufficiency."

Journal • Cushing’s Disease • Endocrine Disorders • Inflammation • Nephrology • Ocular Inflammation • Ophthalmology • Pediatrics • Renal Disease • Uveitis

Stenotrophomonas maltophilia endogenous endophthalmitis in an immunocompetent eye in Australia. (PubMed, BMC Ophthalmol) - "S. maltophilia-associated EE is a rare clinical condition, especially in the absence of systemic symptoms. Despite the poor prognosis typically associated with endophthalmitis, this case resulted in a relatively good visual outcome (BCVA 6/18). This report highlights the necessity for further research to elucidate the epidemiology, risk factors, and optimal management strategies for this rare ocular condition."

Journal • Hematological Disorders • Infectious Disease • Inflammation • Mood Disorders • Neutropenia • Ocular Infections • Ocular Inflammation • Ophthalmology • Pain • Retinal Disorders